11758
document
Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .
11759
Intervention_Pharmacological
intravenous synthetic human secretin
11760
Intervention_Pharmacological
intravenous infusion of synthetic human secretin
11761
Intervention_Pharmacological
2 IU/kg of intravenous synthetic human secretin
11762
Intervention_Control
intravenous saline placebo
11763
Outcome_Mental
language
11764
Outcome_Mental
behavioral symptoms
11765
Outcome_Mental
assessments of language , behavior , and autism symptomatology
11766
Outcome_Mental
mean scores on any measure of language , behavior , or autism symptom severity
11767
Participant_Condition
autism
11768
Participant_Age
children
11769
Participant_Condition
autism
11770
Participant_Sample-size
Forty-two
11771
Participant_Age
children
11772
Participant_Condition
autism